Literature DB >> 20181846

Neuroprotective effects of C-type natriuretic peptide on rat retinal ganglion cells.

Jia Ma1, Wenhan Yu, Yun Wang, Guiqun Cao, Suping Cai, Xiaoming Chen, Naihong Yan, Yuansheng Yuan, Hong Zeng, Debra L Fleenor, Xuyang Liu, Iok-Hou Pang.   

Abstract

PURPOSE. To evaluate the potential neuroprotective effects of C-type natriuretic peptide (CNP) on rat retinal ganglion cells (RGCs). METHODS. Cultured adult rat retinal cells were treated with vehicle, CNP, or atrial natriuretic peptide (ANP), followed by cytotoxic insults (glutamate, TNFalpha, or withdrawal of trophic factor). RGC survival was analyzed by counting Thy-1-positive cells in each well. For in vivo evaluation, N-methyl-d-aspartate (NMDA) with or without CNP was injected intravitreally into rat eyes. At various time points after injection, retinal cross-sections were analyzed for thickness changes in the retinal layers, and retinal flat mounts were assessed by counting cresyl violet-labeled or TUNEL-positive cells. Expressions of natriuretic peptide receptor-B (NPRB) and apoptosis-related genes in retina, including Bcl-xL, BAX, and micro-calpain, were analyzed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). RESULTS. At 50 and 500 nM, CNP, but not ANP, significantly (P < 0.05) protected against glutamate-insult and trophic factor withdrawal-induced RGC death in vitro. Neither peptide significantly affected TNFalpha-induced cytotoxicity. Intravitreal injection of NMDA (20 nanomoles) significantly (P < 0.05) decreased the thickness of the inner plexiform layer (IPL), induced cell loss, increased the number of TUNEL-positive cells in the RGC layer, and upregulated the expression of Bcl-xL, BAX, and micro-calpain. All these effects were significantly (P < 0.05) alleviated by concomitant injection of CNP (4.5 nmol, 10 microg). The neuroprotective effects of CNP were maintained up to 14 days after CNP injection. CONCLUSIONS. CNP protects rat RGCs against the apoptotic damage induced by insults such as excitatory amino acid, both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20181846     DOI: 10.1167/iovs.09-5049

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  13 in total

1.  Evidence-based pathophysiology of glaucoma.

Authors:  Cristina Alexandrescu; Ana-Maria Dascalu; Costin Mitulescu; Aida Panca; Ruxandra Pascu; Radu Ciuluvica; V Potop; Liliana Mary Voinea
Journal:  Maedica (Buchar)       Date:  2010-07

Review 2.  Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.

Authors:  Lincoln R Potter
Journal:  Pharmacol Ther       Date:  2010-12-24       Impact factor: 12.310

3.  Neuroprotective effects of C3 exoenzyme in excitotoxic retinopathy.

Authors:  Yun Wang; Ying Wang; Qiaona Yang; Liheng Guo; Yan Yin; Ning Fan; Xiaomin Zhou; Su-Ping Cai; Paul L Kaufman; Xuyang Liu
Journal:  Exp Eye Res       Date:  2014-06-11       Impact factor: 3.467

Review 4.  Inducible rodent models of glaucoma.

Authors:  Iok-Hou Pang; Abbot F Clark
Journal:  Prog Retin Eye Res       Date:  2019-09-23       Impact factor: 21.198

5.  C-type natriuretic peptide functions as an innate neuroprotectant in neonatal hypoxic-ischemic brain injury in mouse via natriuretic peptide receptor 2.

Authors:  Qingyi Ma; Lubo Zhang
Journal:  Exp Neurol       Date:  2018-03-05       Impact factor: 5.330

6.  Thioredoxin interacting protein is a novel mediator of retinal inflammation and neurotoxicity.

Authors:  Mohammed M H Al-Gayyar; Mohammed A Abdelsaid; Suraporn Matragoon; Bindu A Pillai; Azza B El-Remessy
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

7.  C-type natriuretic peptide in Parkinson's disease: reduced secretion and response to deprenyl.

Authors:  E A Espiner; J C Dalrymple-Alford; T C R Prickett; Y Alamri; T J Anderson
Journal:  J Neural Transm (Vienna)       Date:  2013-12-05       Impact factor: 3.575

Review 8.  C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target.

Authors:  Natalie G Lumsden; Rayomand S Khambata; Adrian J Hobbs
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

9.  Atrial Natriuretic Peptide Promotes Neurite Outgrowth and Survival of Cochlear Spiral Ganglion Neurons in vitro Through NPR-A/cGMP/PKG Signaling.

Authors:  Fei Sun; Ke Zhou; Ke-Yong Tian; Xin-Yu Zhang; Wei Liu; Jie Wang; Cui-Ping Zhong; Jian-Hua Qiu; Ding-Jun Zha
Journal:  Front Cell Dev Biol       Date:  2021-06-23

10.  In vitro and in vivo neuroprotective effects of cJun N-terminal kinase inhibitors on retinal ganglion cells.

Authors:  Byung-Jin Kim; Sean M Silverman; Yang Liu; Robert J Wordinger; Iok-Hou Pang; Abbot F Clark
Journal:  Mol Neurodegener       Date:  2016-04-21       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.